Cytisinicline and the Future of Nicotine Dependence: Rick Stewart, Achieve Life Sciences

What if we could help millions quit smoking with a naturally derived compound that's been used for decades—but never brought to the U.S. market until now?In this episode, Rick Stewart, CEO of Achieve Life Sciences, shares how cytisinicline is redefining smoking cessation after receiving FDA acceptance for its New Drug Application (NDA)—a major milestone in the fight against nicotine dependence.What we discuss:• FDA acceptance for the cytisinicline New Drug Application (NDA) and what comes next• Why cytisinicline represents a breakthrough in smoking cessation• Commercial readiness and go-to-market strategy• Financial strategy and capital efficiency in late-stage biotech• Market impact and public health implications of a new smoking cessation therapy• Investor relations and communicating clinical value to stakeholders• Personal reflections on leadership and building Achieve Life SciencesThis isn't just another smoking cessation drug. This is a naturally derived therapeutic with the potential to transform public health and save lives at scale.About the Guest: Rick Stewart is CEO of Achieve Life Sciences, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence.About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.🔗 Connect:• Achieve Life Sciences: [https://achievelifesciences.com]• Rick Stewart: [https://www.linkedin.com/in/rick-stewart-9597654]• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]📧 Questions or guest suggestions? [[email protected]]#Biotech #SmokingCessation #Cytisinicline #PublicHealth #DrugDevelopment #FDA #NDA #ClinicalTrials